Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease

Young-Hak Kim1, Seong-Wook Park, Seung-Whan Lee

  • 1Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Circulation
|October 25, 2006
PubMed

Insights

Sirolimus-eluting stents (SES) significantly reduced restenosis and revascularization needs in long coronary lesions compared to paclitaxel-eluting stents (PES). This finding offers improved outcomes for patients undergoing coronary interventions for complex lesions.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomaterials Science

Background:

  • Coronary interventions for long lesions have suboptimal outcomes.
  • Drug-eluting stents aim to improve these outcomes.
  • Sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) are commonly used.

Purpose of the Study:

  • To compare the efficacy of SES versus PES in treating long native coronary artery lesions.
  • To evaluate restenosis rates and the need for revascularization.

Main Methods:

  • A randomized, multicenter, prospective study involving 500 patients.
  • Patients received either SES or PES for long coronary lesions (>= 25 mm).
  • Primary endpoint was in-segment restenosis at 6-month follow-up angiography.

Main Results:

  • SES demonstrated significantly lower in-segment binary restenosis rates (3.3% vs. 14.6%, P<0.001) compared to PES.
  • In-stent late lumen loss was significantly lower with SES (0.09 mm vs. 0.45 mm, P<0.001).
  • SES group showed a reduced rate of target-lesion revascularization at 9 months (2.4% vs. 7.2%, P=0.012).

Conclusions:

  • SES implantation is superior to PES for long native coronary artery lesions.
  • SES reduces angiographic restenosis and the need for target-lesion revascularization.
  • No significant difference in death or myocardial infarction rates between the groups.
Abstract

Related Concept Videos

Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...